<SEC-DOCUMENT>0001193125-15-044272.txt : 20150211
<SEC-HEADER>0001193125-15-044272.hdr.sgml : 20150211
<ACCEPTANCE-DATETIME>20150211163638
ACCESSION NUMBER:		0001193125-15-044272
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150211
FILED AS OF DATE:		20150211
DATE AS OF CHANGE:		20150211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15600037

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d871241d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 11&nbsp;February 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g871241001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Shares on issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 M</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of
Directors</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman &amp; Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11 February
2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOVOGEN LODGES KEY SUPER-BENZOPYRAN PATENT</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, Australia</B><B>:</B> Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced
the lodgement of final specifications of a patent that covers the Company&#146;s first family of super-benzopyran compounds that to date has yielded leading drug candidates, TRXE-002, TRXE-009 and TRXE-0025.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Super-benzopyrans represent a new chemical structure of increasing complexity and
diversity. Based on the degree of that complexity, Novogen chemists have identified at least 6 patent families of related compounds. The final patent specifications just lodged represent the first of those families, with some hundreds of molecules
designed and manufactured over the past 12 months. The focus with this particular family of compounds has been their ability to kill cancer stem cells. The underlying pharmacophore responsible for this activity has been identified and forms a key
aspect of the patent.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Work is progressing on the remaining 5 potential patent families
to determine the underlying pharmacophores relevant to various activities including the promotion of neurogenesis, to the promotion of functionality of stem cells with genetic abnormalities, and to the treatment of lysosomal storage diseases. Once
those potential patent families have been reduced to practice, then the appropriate patents will be lodged.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Heaton PhD, Novogen Group Vice-President of Drug Discovery and Manufacture, said, &#147;The last 12 months has been a highly productive time of reducing
our super-benzopyran drug discovery program to practice, so allowing this PCT final specification to be lodged. Happily we also are seeing these drugs successfully come through their large-scale manufacturing process ahead of a number of clinical
trials over the next 12 months. We have not hit any manufacturing hurdles, confirming the simpler manufacturing process that is a key part of the patent.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graham Kelly PhD, Novogen Group CEO, said, &#147;Andrew&#146;s drug discovery team has delivered an exciting opportunity to the Company. These new families of
not previously seen compounds are proving an extraordinary rich source of potential new therapeutics. It is remarkable that the same underlying molecular structure can yield compounds of such diverse biological activity. This pleiotropy is what
makes this family of compounds so valuable.&#148;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#147;The lodgement of this patent
also opens the way for our collaborators to present data for conference presentations and publications where disclosure of molecular structure is required,&#148; Kelly added.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page&nbsp;&nbsp;|&nbsp;&nbsp;<B>2</B> </P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ
(&#145;NVGN&#146;). The Novogen Group includes a New Haven CT &#150; based joint venture company, CanTx Inc., with Yale University. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main
drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament
component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell&#146;s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate
cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our websites <U>www.novogen.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4100</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristyn Humphreys</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cristyn.Humphreys@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472
4111</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934.&nbsp;The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements.&nbsp;Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, and any other statements that are not historical facts.&nbsp;Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the
difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for
the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Company&#146;s two proprietary technology platforms, and other&nbsp;risks detailed from time to time in the filings
the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.&nbsp;Such statements are based on management&#146;s current expectations, but actual results may differ materially due
to various factions including those risks and uncertainties mentioned or referred to in this press release.&nbsp;Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g871241002.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g871241001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871241001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"4`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]1;G4OL\S1^7NQCG=C^E1?VS_`-,1_P!]_P#UJK:G_P`?C_0?RJK0
M!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_Z8C_`+[_
M`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS_P!,1_WW
M_P#6H_MG_IB/^^__`*U9E%`&G_;/_3$?]]__`%J/[9_Z8C_OO_ZU9E%`&G_;
M/_3$?]]__6H_MG_IB/\`OO\`^M6910!I_P!L_P#3$?\`??\`]:C^V?\`IB/^
M^_\`ZU9E*,9%`%AO$^&(^S=#_P`]?_K4G_"4?].P_P"_O_UJYR_OH+!6>ZD5
M,Y*@GEOH*Y;4_%$UR"ED&@C/4Y^8_P"%5&-S&K7A#=ZG>ZE\0[;3%(EMR\N,
MB-)<G\>.*RA\601D:5_Y-?\`V->>$DDDDDGKFDK3D1PSQ<V_=T/1?^%L_P#4
M*_\`)K_["C_A;/\`U"O_`":_^PKSJBCD1'UFKW_(]%_X6S_U"O\`R:_^PH_X
M6S_U"O\`R:_^PKSJBCD0?6:O?\CT7_A;/_4*_P#)K_["C_A;/_4*_P#)K_["
MO.J*.1!]9J]_R/1?^%L_]0K_`,FO_L*5/BPA=1+IC*A/)6XW$?AMKSFBCD0U
MB:O<]BM?&<-['OMH5=>^)>GZ5-_PE'_3L/\`O[_]:O';:ZFM)`]M(T;CNIZ_
M7UKI--\5(X6/40$;IYB_=/U]*B4+;'72Q49:2T9WW_"4?].P_P"_O_UJ/^$H
M_P"G8?\`?W_ZU8,;K*@>)E9&'!!SFEJ#KZ7-W_A*/^G8?]_?_K4?\)1_T[#_
M`+^__6K"HH`W?^$H_P"G8?\`?W_ZU'_"4?\`3L/^_O\`]:L*B@#=_P"$H_Z=
MA_W]_P#K4?\`"4?].P_[^_\`UJPJ*`-W_A*/^G8?]_?_`*U36_B#SRW^C[=H
M_P">F?Z5SE6]/ZR?04`;O]L_],1_WW_]:C^V?^F(_P"^_P#ZU9E%`&G_`&S_
M`-,1_P!]_P#UJ/[9_P"F(_[[_P#K5F44`:?]L_\`3$?]]_\`UJ/[9_Z8C_OO
M_P"M6910!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_
MZ8C_`+[_`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS
M_P!,1_WW_P#6I#K849:(#_@?_P!:LN1_+7(&:K/(7.6H`V#XB':#/_`__K4?
M\)%_T[_^1/\`ZU8M%`&U_P`)%_T[_P#D3_ZU'_"1?].__D3_`.M6+10!M?\`
M"1?]._\`Y$_^M1_PD7_3O_Y$_P#K5BT>M`#-2^)']G7LMN=.\SR\?-]HQG(!
MZ;?>JW_"UO\`J%G_`,"O_L:Y3Q+_`,ANY_X!_P"@BLL^O:MHQ6AYE3$5%-I,
MZW5OC-=Z<IDM_#OVN(#+%-0PR_5?+_E6`/VE\D`>&R23@#^T>_\`W[J*VL);
MC!`")ZFEN/"]B-]Q#!&MV%XE"@%C5KV2T:.:I+&O6%2R]%_D=#I_QKN;N/?<
M^'OLJD94-J&6/U'EC%6_^%P_]0C_`,G/_L*\X)Z4E-TX=B%C*Z5G+\%_D>D?
M\+B_ZA/_`)-__84?\+B_ZA/_`)-__85YO11[.(_KM?\`F_(](_X7%_U"?_)O
M_P"PH_X7%_U"?_)O_P"PKS>BCV<0^NU_YOR/2/\`A<7_`%"?_)O_`.PH_P"%
MQ?\`4)_\F_\`["O-Z*/9Q#Z[7_F_(](_X7%_U"?_`";_`/L*HZC\;KJR7?!X
M<-S&!\VV_P`,/P\O^M<+2AJ:IP6Z%+%UVM)V^2_R-\?M,#OX<(_[B/\`]KH_
MX:87_H7?_*C_`/:JXS5/#]KJ8+%1%,>DBCK]1WKD=3\/76F$ET\R(?\`+1.G
MX^E;0I4I=#SJN.S"GKSW7HO\CV'_`(:87_H7?_*C_P#:J/\`AIA?^A=_\J/_
M`-JKPS'%&*OZM2['/_;&-_G_``7^1[G_`,-,+_T+O_E1_P#M5+_PTPO_`$+O
M_E1_^UUX7BN^\%_#@:M;0ZAK#LMK+\R01\,Z^I/8?3FIG1HQ5VC?#X_,:\^6
MG*[]%_D>A:3\?[W6[GR-,\*23-_$?[1PJCU)\K`%=U;^-9'A4W-@D<I'S(ES
MO`_':/Y5RUCI]MIELL&GP1P0KT5%Q^?K4]<<^1_"K'TV'A7BOWL[OT2.JB\6
M>:#_`*+C'_37_P"M4R^)03AK<J/7S,_TKF;3HWX5;K)[G4MCHAK8896($?[_
M`/\`6I?[9_Z8C_OO_P"M7.JQ1LJ<&K4-QYAVL,-_.D,V/[9_Z8C_`+[_`/K4
M?VS_`-,1_P!]_P#UJS**`-:#53/,J>5MW'&=^?Z5H5@V/_'W%_O5O4`8>I_\
M?C_0?RJK5K4_^/Q_H/Y55H`****`"BBB@`HHHH`****`"BBB@`I0,TG0<]JQ
M]3\3P6>4M?W\HZ[?NC\>]-)LF4HQ6KL:TLL<$9>9U1!U9C@5SNJ>*PKE-+&[
MG'FL/Y#_`!K"O-0N-1?==R,P!X4<*/H*@QCI6B@CSZV+E+2.B,RYN9+N9I+E
MVD<D\L<U%2GJ?K25?2QR!1110`4444`%%%%`!1110`4444`%%%%`BY8ZK<Z>
M3]GE(4]48Y!_"NIT[Q';7VU)3Y,Q_A)^4_0UQ5`XS[U+BF;TJ\H:'I=%<3IO
MB*YL"$D8SQ=-C'D#V/\`C75:?JUMJ2`V[X?',;<,*AP:/1IUX36^I<HHHJ#8
M****`"K>G]9/H*J5;T_K)]!0!:HHHH`****`"BBB@`HHHH`****`"BBB@!ES
M_JQ56K5S_JQ56@`HHHH`****`"@#)XHIK-@\4`<=K]N]QK=P(@3]S)QP/E%)
M;Z:D6#+\[>O85JZC_P`?LA/?'\A5:MNAYSI+F;`<#`IDOW&_W33Z9+]QO]TT
M%2V..-)2M25NMCQY;A1110(****`"BBB@`HHHH`*&PP(8`@]11136@&%JGA.
MWO`9+'_1YO3/R-^':N2O=.N-/EV7<;(W8GH?H:]*ID]O%=1&.XC1T/4,,U<*
MC3U.6KA(SU6C/+Z]]\%?\BII7_7LM>5ZIX-*AI-,?/<Q.?Y'_&O5O!T;1>&-
M-212K);JK`CH:6(:<4S?):,Z>(ES=OU-FBBBN0^H+5IT;\*MU4M.C?A5NLWN
M4M@J6V_UP^A_E452VW^N'T/\J0RW1110!8L?^/N+_>K>K!L?^/N+_>K>H`P]
M3_X_'^@_E56K6I_\?C_0?RJK0`4444`%%%%`!1110`4444`%+24HZT`<SXKU
M1PPL[<E1MW2D'KZ"N;"@=!6AXA_Y#MR!TPO_`*"*H5NMCQZ\W*;N%!.!D]J*
M#R#3,C(8;68'J#25<N;8G+)][J1ZU4((ZT`)1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4Z.1HI`T;%64Y!'44VC&:!IV9WFB:E_:=BLCX\Q?E?'J/\`
M]=7ZYWP;Q#=#MN7_`-FKHJPEN>Q0ES4TP_$#ZFN0OOC#X"TR\GM-1\<>#[2Z
MMI6BG@GURVC>)U.&5E+Y!!!!!Y%97[0?C^]^&/P=\3>(]%@DGO[*V5+9E7<(
M))'6-9B/1"X<_P"[VZU^2$LTD\KRW#O)+(Q9W=LLS'J2>YS7#B\7[%I)79]W
MPKP@LWHSK5:CC%.RM;5[L_:RQOK;5+*"\TV>&ZM+J-98)X)`\<J,,JRL.""#
MD$<5I6`P9"?3%?)'_!/[XBW^O_#G6/#VMB3[+X4N(_LE[*0$$4^YO)+$]596
M/LKJ.,"OK:TO;-R(K:[MYI#D[4E5B?P%=5*I[2FIVW/E\XP7]G8^IA)R5XO[
MUNOO5BW1115G`%%%%`!1110`4444`%%%%`!1110`RY_U8JK5JY_U8JK0`444
M4`%(3BE'6FMUH`0\G-!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>
M["F2_<;_`'33Z9+]QO\`=--$RV..:DI6I*W6QX\MPHHHH$%%%%`!1110`444
M4`%%%%`!1110`HKOM$&_2+;=S\@K@5ZUUOA[7(#;16MPPAD0;5+'AN>*BHKH
M[L%)*;N;+*5//3L:;4LH^7Z5%61ZY:M.C?A5NJEIT;\*MUF]REL%2VW^N'T/
M\JBS5BWB((=ACT%(98HHHH`L6/\`Q]Q?[U;U8-C_`,?<7^]6]0!AZG_Q^/\`
M0?RJK5K4_P#C\?Z#^55:`"BBB@`HHHH`****`"BE^E<]XC\;Z9X=0K/+Y]UV
MMXF!;_@1Z+347+1$5*D*<>:;LCH.N,<YZ4HZUX7K_CS5M>D(:<VMMGY88&*C
M\3G)_E[5=\.?$G4='V0WV[4+4'[KM^\0?[+=_H<UM]7E8\Y9O0YK.]NYUOB+
M_D/77T7_`-!%4*9-XCL?$.J7$VFS!C\H:)OE=?E'53SCWI]5RM+4PG.,I.47
M=!1112)#&:BFMEE'0`^HJ6B@#-FMVB'(R/45#FM=ER#[U7ELU;++P>X]:`*%
M%/>)HSAQBF4`%%%%`!1110`4444`%%%%`!1110`4444`=3X-_P!3<_[R_P#L
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MX&^-`I`/3`3/S*:\^\#>,K_X?>+--U_1&VW6FS"3;T$J='C/LRD@_6NI\/Z2
M_P`0?AW<V<]S:6=UX0G22RO;Z800FVN7.^W,C?+N$N)$!_O3>E3^#OA?!'K8
MO/$&HZ!JVG:7;S7]SI^F:M%//=K!&TGE*JG.&V88CHNX]J]_#TZ.&H>QZ1T]
M3\8SG&9EG6:O,FVY5&I)]O+Y-?J??-C\5?"EWI]E=7>OZ/IK7UK%<K;7M_%#
M-&LB*ZAT9@P.&'&*Z+3=5LM9L4O=(N[6^LY03'<6TRR1O@X.&4D'!!'7M7Y3
M:_KMYXFUN]U75I/,O+^=I9F`P,D]%'8`8`'8`#M7U%^Q!\0KUGUOP;=I-/9+
M;OJ%I*!D6Q!"R*3V#%E(]P?6O+Q64>RHNI&6W3^NQ]OD?';QV/CA*M.REHI*
M^_2ZZ7_`^L](UO3O$%I]JT#4++4[7<4\^SG69-PZC<I(R/2IK/4+748'FL+F
MWN88G>-Y(9`ZJZ$AU)'&0001V((-?-/[-[?\*XT_P/G,7AWXDZ1#R>4M]9AC
MQ_P'SXAZ\O%[U/IL9U[0/#_@^ZDFBTCQ7\0M?35?)<H;BW@N+R<V[,.0KLBA
ML<E=P[UXQ^CGNNF_$;PIK.KG2M(\3:!>ZF"1]C@U*)Y21U`0-DFMFTU&TOYK
MF*RNK>XELY/*N4BE#F%\`['`/RM@@X/."#7(^,?A)X6\4^#YM&.D:=IZ0PDZ
M?<6=ND+Z?*H_=RQ,N"I4@'@C..>*\K^!_BB\7QEX;U+66;;\4_"L-Q+*W_+7
M5;!1'*P'0>9`5?C^Y0!]`OJ5G'J$5A)=6R7T\;2Q6K2J)712`6"YR5!(&1QD
M@5BR?$KPC%K(TB7Q3X=352_E_8FU.$3;LXV[-V<Y[=:\*\::M<^(?$'C7Q!I
MUS/:QWFLZ9X!TZ^@?8]K`URGV^1#V8O*8PPZ&,>E>W-\*/!A\+_\(X?#.C'1
M?*\LVAM5QC&,[OO;^^_.[/.<T`=/<3Q6D#S7<D<,,2EGDD;:J@=22>U8>C?$
M'PMXBOFLM`\2:#J5ZO6WM-1BFD]_E5B:\(\((?'NI^$O`7B^>75=$\/SZX;I
M+H9&K?V?>);6BR_WU59=Q!R&903G%>^1Z)X;T.]T^2/3]$L+T%H-/9;>**0$
MH24BX!^XK9"]@>PH`JW7Q,\'V5U+;7GBOPU#<0.8Y8I-6@5D<'!5@6X((P0:
MUQKNFMJW]E)J%BVIB'S_`+$+A?.\O^_Y>=VWWQBO$/A=XETFUM=8M+[P;KVJ
M3GQ9K"M?VWA\W,)W:A-_RUQT7.#Z8/I6?\1]&O8/BYXM\9>&(VFUWP+IFC7\
M4"#FZM&^V"[MO^!Q98?[4:4`?0-UJ-J+M;$W-O\`;6B\X6_FKYGE@XW[<YVY
M(&<8S3:\RM=7M/$'QVT74](G6YL-1\`O<VTR])(WO(RI_(BO3:`"BBB@`'6F
MM]XTX=::WWC0`E!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>["F2
M_<;_`'33Z9,0L3LQP%4Y-,F6QQS4E*:2MUL>.]PHHHH$%%%%`!1110`4444`
M%%%%`!1110`9Q1DT44`2W/B^[\.67FH!<P(Z@Q2$_=)&<'M71^'?&>F^)$Q9
MRF.XQEK>7`8?3L1]*\^\6?\`($E_WT_]"%<-&[1.KQLR.IRK*<$'U%:*C&<;
MF,LRJX>KR[KL?4%F<J_L16A'`TG^R/4UP/P6UV]U^UU-=6F-Q]C,2Q,X&0&W
MYR>_0=:]*["N"<>631]/AJ\:U)5([,9'"D62!DGN:?114FX4444`6+'_`(^X
MO]ZMZL&Q_P"/N+_>K>H`P]3_`./Q_H/Y55JUJ?\`Q^/]!_*JM`!1110`4444
M`%5=5U6VT6RDN]0D\N&/J0,DGL`.YJV.M<3\7?\`D6(O^OU/_07JHJ[2,,34
M=.C*:W1R_B7XHWVIEX-'#6%L<C?NS*X^O1?P_.N(8EV+.<L3DD\DTE%=ZBH[
M'R%7$5*KO-W"BBBF8',ZG/)::L\MK(\4B$%61L$<"NK\/_$N2,+!KR-*N?\`
MCXC'('^TO?\`#\JY#6_^0E+]1_Z"*HCK6W+&4=3&%>I2DW%GT#;SI<PI+`P>
M.10R..C`C(J2LSP;;2OX:T[Y=H-NN"W&:VS8R8RNT^V:X)*SL?2TTY13MN5Z
M*4JR$B0%3GO24AO3<****`$90PP<54FLN\9'TJY10!D$%3A@0?>DK4>!9!AN
M:J2V;+DIR/2@"M12D8-)0`4444`%%%%`!113D1I&PBD_TH`;4L<#2'Y>GK5F
M"R`YD.3Z5:`P.*`.@\$6RI#=MU(9>OT-=0.U<[X-_P!3>?[Z?UKHSUK&:]X]
M;#?PD0WMI!J-I/:WL2S6US&T<T3C*R(PP5/L037Q?KW["GB<ZW>_\(SK/AY=
M),[&R%Y<3B98B<JK@1$;@"!D$YQ7VK171AL95P]^3J>;G&08'->3ZU%OEO:S
MMN?G%\9_"-_\)+/2/`]XJLP3^U+^\BSY5].^Z-=A(!*1HI49`.YY#C#"O._#
MVO7OA;7+'5M&E\J]T^9986QD9!Z$=U(R".X)%?H9^T%\"X_C7H5A#:74.FZK
MI=P7M[N2,NIC<`21L!S@X4@]BN.YKR;X??L23^'?&.EZGXLUO3=4TW3YO/DL
MXK=U,[+RBG=QMW;21W`QWKV\/F5'V%ZCUZKN?EN:\&YDLSY<+!NGIRRNO=6F
M]]=#D+[]C'Q-XFN/[8\-76A:/I>JQQWEOIVHSSK-9"1`[0.%B8?(Q9.O(4$\
MU]!?L\?`\_!KPA>6^IS6EWKFJRE[RXMLF,(N1&BEE!*@$MT!RY]J]<Z#`&`*
M2O&KX^O6AR2>A^CY;PIEN`Q'UFE%\_=O37=I=#RFQ^#-Q<?`+2_`NLW-O#K.
ME6$0M+^U9BMK?0MOAF1BH;"R`=AD;AWJEH_P6UR7X=65AK.JV&F^,--\0W6O
M6>H::'GMX;F6>63;M<(SQLLS(R\<'J<<^QT5QGTAYGJVE_$_Q7I,^BZE_P`(
MCX<AO(C!>ZMIM_<74XC(PYMX7AC5'(S@L[;<YPV!3_'/PLN9O!WA:R^&C6%A
MJ_@:[M9]#^VLRQ%(U\IX9&56;:\3,#@')`KTFB@#S'1O@G!!\$;;P+JU](+S
MR1+<:G;/N=;_`,WSS<HQ`)(G^8$X)``/>I5?XLC3_L+0>`A>*OE_VT+RY8$=
M/-^R>2/GQSL\X+N[XKTFB@#RNZ^"<VD^'_"__""ZN;7Q-X1>XEM=1U!&F34&
MN#NNDN0#G;*YWG:<JP!7CBGW'ASQYXI\4^$+WQ;8^%-/M?#.J/>S2Z?JL]P]
MPS6TT&U(WMT"C,V>7.,=Z]1HH`\M\):!X^\$VFIV%AIO@N^L[C6;^^AFFUNY
MA?9<7,DP#(+1AD!\'YCTZ]ZZC2/"MY8?$CQ/X@N'MC9ZU8:=;P(K$NKVYN-^
MX%0,?OEQ@GOP*ZJB@#Q_X:_!G5_`'Q*O]0-WIDOA*WL+BST*UC9_M-M%/<+<
M>4X*A=B/YBJ0Q.-N:];D@S_J_P`JEHH`I$%3AA@T5=*AAAA5>2W9>5Y7U-`$
M0ZTUOO&GXP:8WWC0`E!Z44'I0!AZC_Q^2?A_(56J76+B.VN9&F8*!C^0KG+W
M77ERMH#&O]]NI_PK=1;2/.J58P;N:MYJ$-DO[QLOV0=36#?ZK+>`J/W<1_A7
MO]35-B6R222>22<YIM:*"1P5,0Y:=`HHHJC!NX4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`,;Q;_`,@27_?3_P!"%<*.E=UXM_Y`DO\`OI_Z$*X4=*ZJ
M7PGD8W^+\O\`,]D_9]Y@UW_>M_\`VI7K/:O)?V??]1KO^];_`/M2O6NU>=7_
M`(C/KLJ_W2'S_,****Q/1"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;U`&'J?\`
MQ^/]!_*JM6M3_P"/Q_H/Y55H`****`"BBB@!1UKB?B[_`,BQ%_U^I_Z"]=L.
MM<3\73_Q3,7_`%^I_P"@O5T_B1RX[_=I^AX_1117H'Q@44^*&2XD"0J78]A6
M_I_AI0`^H$,?^>:GC\:3:1M2H3J/1'G]SI-SJVJS"SC+*&`9SPJ\#J:Z32?"
M-M8;9+K_`$F=>02/E7Z"NCNXTBF98E5%'0+P!Q_]:HAT-)U&]C>GA80=WJSM
M=*&-+M<8`"<`=JM56TO_`)!=M_N59KD;N?14_@0UXDE3;(`:IRV#1_ZK#`]N
MXJ]0#BBX3IJ1DY]>"*,UI36T=P/G^5O[PJA-:O">F5]157.65)IC**0$'H:6
M@R"BBB@"*6V249.0?451E@:(\\CU`K3I"@/6@#(HJ_+9J^=GRD56-K("1M)^
M@H`AI5&XX'6IX[-V^\"H_6KD4"Q#Y<Y]:`*L5D>LGY5;2%4&$&!3Z*`"BBB@
M#IO!O^IO/]]/ZUT9ZUSG@W_57G^^G]:Z,]:RGJSU\,OW*$HI<48J#8,=?;FD
M]?;K[50U_2;77-%N['4K:*\@FC),,@R&8<KQZ@@'->=_\(?J>G_!CP]IGAVV
M_L_6Q/HD]X#$6*2I<VQN))%5U+X57+#<,A3SSP`>J`%L8YR,C%)7DVI>'_%+
M^!?BO:Z@_P!NU;5&N#ILEG`\"SYTRVC3RD,CL/WBLOWN64GC-=OX!L$TWPW#
M;QV\-LR2.76'3)-/0L3G*PNS,.W))R030!T8&3@=?2C!':N$D\*WUS\89];D
MCLO[-M=*LXX'N+1I)#+NN]_DR"0",@-'NRC9!'3BLF?3M;/B;^SDL=3VCQ?'
MJHO,?Z.UDL"Y/F9P/G!3R_O9.=NWYJ`6IZA2XYQW%</<>";1_BM::R-,B:)=
M,FDDN]O'VL2Q>6W^_LWX/ID9[5D7EIK`\1W^EQ:9J;+>^*K+48+P+_HZV4<-
MOYF9"<#YX9%\O[Q+`X(;-`'IXY&1TH"E@"O.>F*\D\0>$-=G^*T&MVUNO]EQ
M7]BLDT43?:A&(Y`Q1]^/*WF-9$*G*L2#\HK7@T2X7XR7VHWMK'):O!"MG,^E
MRRL#Y3!RMP'V1C+-E2A))Z\T6`]$`)Z4F<G`ZUS?Q%LM1U#P=?0:"+F2Y=X&
MD@M9O)FN+=9T:>*-]R[7>$2H#N'+#D=1B>`M)>UU_6Y]$TR^T7PU/96RV]E=
M*T&^[4R^=*D)YC!5HE)P-[*6`XW,`=^.1D<BBN'^"_A2]\(_#W2;77([*+4I
M+.W>Z6WM&@82^2@82YD??(&#9?(!/85W-`"444N*%J`E%%%`#3&K9XP3WJI(
MC*YSS]*NU#)]YOK0!5Z].M.$18?,.#4H4#H!3AUH`\V\8$_V_<J22%V8!/3Y
M!6+6SXP!'B&[S_L?^@+6-79'8^=Q'\67J%%%%,Q"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`QO%O\`R!)?]]/_`$(5PHZ5W7BW_D"2_P"^G_H0
MKA1TKJI?">1C?XOR_P`SV/\`9]_U&N_[UO\`^U*]:[5Y-^S^I6VUMB"%9X0#
MC@D!^/UKUGM7G5_XC/KLJ_W2'S_,****Q/1"BBB@"Q8_\?<7^]6]6#8_\?<7
M^]6]0!AZG_Q^/]!_*JM6M3_X_'^@_E56@`HHHH`****`"N:^(6AW.O\`A\PZ
M<HDGAF658^A<`$$#WYKI:1G"''4]Q33L[F=6FJD'![,^;IH)+>=H9XWCF4X:
M-E(8'TQ6MI_AV6?Y[L^2G]TCYC_A7L^J:1:ZLX>ZA1I$4A)0,,H]`:Y?4_#5
MQ8C?#F>(=UZK]1_A74JZ:MU/"EE7LGS/5&!;6<-I'LMD6,'J1U/XU/1VS2JI
M=@J`DGH!2UO=EI):(R;[FX;\*9;V\ES)Y<",[GL.WU]*WE\-22W)>_)B3@[`
M/F/^%;-O:Q6D02W144>G]30YHJ&&<G>6@EG";:SAB<@M&N&QZU+1161Z$596
M"BBB@84`X_&BB@"O+9I)EH\(W\ZIRQ/`V)!QZXXK4H8!EPP!![$9JDS&I14M
M49`8'I2U:FL!DFW/_`355_D;:X(;T(IG+*$HO4****"`HHHH&%%%%`!1110`
M4444`9^O?%C2OA=I\?\`:-MJ&I:EJ]PL&FZ9IT/FW%VXZA5XSC*_F.#72_#7
MXBR^/X-0^W^&O$'AF[TV14EAU:W\OS"P)!1OX@`.>.,CK7G?C7P1XEU37/#7
MB_X=Q6=_K'@^ZG)TV[E$2W<5Q&$<*YX5@JD<D?>SG(P?1OAWK?C776U"?X@^
M'=.\-VVZ-=/M8=1%U-C!WF5E^3&=N,$'J".`3K4A#V*DK7]=5KV,,'7Q+QKI
MU&U!/1*%XM<M[N=M'S75KKIIK<R]7^-VC:-\6=.\!SV]T]]?QJ3=KM$,$CJ[
M)$V3G<P08_WAZ&M#XN_%*R^$/A,:]JUG=7UL;N.W,=L5#98$@_,<8^6O!]>^
M!7Q'U^3Q'XRANK>QURX\10ZE8:%)%"\D@MF*VQ^T^9A=L4C_`"]#CZ5ZE^T/
MX/U[XC_#;3;/P_IHEU`ZI:W5Q:2SQCRD56W@LS;3@D#@G-5*CAU.FD].IST\
M?FD\-BG*DU)7=/W>CO96UNU;5/77;8Z/1?BWI?B+QS8>'=&AGN%U/P\NN6]^
MK+Y1A:0QA",[@V1GVJA\1?C79^!==M=`TS1-:\4^(KN`W']FZ3!YCP0Y(\R0
M_P`()'OVSC(SQ/PK^"&L_#?X[:C?6R^=X-31YH-(E,RDVJRSK-]FVYW#:YEP
M<8((.<G`T_&WA#QCX1^+LGCWX<Z3:>)8=6TM=/U'3)+Q;26,JPVR([_+MPB\
M=<YXYR!TL.JMD[JW>UWYOH7]<S26!<YP<9\]G:-VH]TOM:[/71WUL>D>#/&/
M_"8>%H]9?2-6T5B9%DL=3M_*G1D)#9&>F0<'O7$_##X]O\4]0LAIW@[Q-9:7
M>K*4U:YB4VH*9!&\'J64K]:[+P;=>)M7\*-+X]TW3]*U><R[;.RN?.6*,D[%
M9NF\`X."1D9XS@>'_LV?#+Q+\--3L(?$7@.:TN989X;W7?\`A(TE18RQD4"U
M5B,DJBY'/?N:B%.DX5&]UMK_`,'7\2Z^*QL<3A(POR23YGRZ[QM=<KY;ZZ/E
M]3T3XE?'BW^'/BR+04\-:YK]VVE_VE)_9JH_EP!W5B02#@;"2>G-=UX-\66'
MCKPOIVO:$TC6&IPB2+S``Z\D%6`)`(((/)Y'>O%OC/\`!77?B5\4C>Z;/=Z;
MIO\`PB,EG'?V]ZL.;OS9&6*1<[FC8.`P`P0>M>H?![3;_1?AKH.FZ]I$6AW^
MG6JVTUI%,LJY3C>&4D'=][KG).<]:*U.BJ,91^+J:9?B,QEF=:%>+]EKRZ66
MC75+\]^FS+?Q!\977@C1(]0T_P`/ZSXD=[@1/:Z7$'DC4JS&1A_=&T#_`(%7
M,_"7XV-\67#V/A77M+TQ[9YH=4NT4V\S)($,:L.K9+<?[)KT>[C:6TG2,?-)
M&RCG')'_`-:O/?V=O!VK>!/A!HFB>*;;['J-HUQYL/F+)LW3R.OS*2#PP/7O
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M6^IWT:BWGPRJ$5AU)R3_`,!-9?Q`_:+M/`7B_4]#?PQX@U?^Q;.*\O[JP1'2
M"!@#O8$Y`&>2<"N>_9G\!Z]\.I?L6N^")=$DGLMM]K!\1)=I<.C955MU)\O.
MYNAQQ61\8/@)XG^('Q%\9ZII;W=C;76@PIIDL-^D4=]/'LW6\J[@Q5@&`)PN
M<$GC%:JCAO;R3:Y>FOGY,X:N,SC^R:52G%NLWJN76W*W:SC'2Z2O;RNV?0^@
MZY:>)-!L=8TMRUEJ5K'<P/(NT^6ZA@2.QP:XGX1?''1?C#-K4>@VUS:G1YE7
M-PR_Z1&Q8+(F#T^1LCMWJ'6+/Q*_P%ET[P]X>&G^)'T5;"+28;B)%M&($1V/
MOV[53<ZG=G`&>>*X7X:?!CQC\*/B-X>O?MUIK^CSZ*VE:B]O:1V9L4CP\1*^
M83,2Y(W@;L9S6,:5+DFVU?6VO;_,]&KC<?'$X90IMP:7.U'K+1;ZJSU:MHM[
M'9_$KX[P?#SQ8F@1>&]>U^\.E'4Y#ID:OY<`=U8D9S@;,D^];<GQ5L;GX4GQ
M[X?L;W5M-%H;K[-"56;8I(D&"<93#9&?X3BN#^)OP6U/XB_&ZVU!KO6-)\.#
MPP;*?4-)OXX)6F\Z0F`@[CL9'Y^7!XKUSPKX3T[P;X8L=`T.'9IUA`8HD<[B
MP))8MZEB23ZDFE46'C3A;?J:8669UL57532GJHMI7OI9K2[6^][]#D?"GQNT
MKQQXML-$\*V=Y?+<Z-'JEU>J5$5BL@^6*3G/F$XX]_8UZ,>O'2O(_P!G?X93
M_#:P\5Q:CI<.FR7_`(AGDL_+E20O9*%$`RI.`,O@'D;CQS7K=8XA4U.U/8Z\
MGGBYX6-3%?&^EK6\N_GKW"H7^^WUJ:H7^^WUK$]0;2TE%`')^-="DN"+ZT4N
M47;*H&3@="*XG\#7L58>L>$[35-SQ@6UP?XX^C?45M3J=&>=B<$Y-S@><XQ1
M6EJN@WFD,?M49:/M*@RI_'M^-9P&:W33V/*E"479JPE%!&**"0HHHH`****`
M"BBB@`HHHH`****`"C&:,5>L=(GOB"B^7'_?8<'Z4-V*C!MV*./4@'ZT$8-=
MC8Z5!8K\J[Y"/F=N_P#A2W>EV]ZI$B`,>CJ,$5G[17.KZG*V^IYKXMXT67/]
M]/\`T(5Q=C87&I7<5K80R7%Q,VU(XUR6->T7'PWEUP?9KBZ%O;,RL9`F7(!Y
M`!XS[UV_ASPEI?A6W\O1[98V8?O)F^:1S[M_3I6T<1&,+'$\IJUZW-+2/];%
M7P%X7_X1+P[!:2$-<N?-N&7H7('`]@!BNAI:2N&3;=V?34Z<:<%".R"BBBD6
M%%%%`%BQ_P"/N+_>K>K!L?\`C[B_WJWJ`,/4_P#C\?Z#^55:M:G_`,?C_0?R
MJK0`444O\J`$H9@HY/X4QI>H`_&HCR<GDT`/9R3P<"F444`%'7KVHHH`R]1\
M.VNH-OP89/[R=_J*FT[1[;3`#"FZ0=9&.6/^%7J*?.TB%2@G>VI@:IQ>R@>H
M_D*J5;U7_C^E^H_D*J5HC"6X4444""BBB@`HHHH`****`"DDC25<2<^_>EHI
MW$TFK,HRV+)EHLNH[>E5\_7BM8$BHYK>.<?,"&]133.>I1[&;FBGRV[0.`W(
M/1J93.>2LPHHHH$%%%%`!11FBBP'3>#<>5>9_OI_6NCKG/!O^IO/]]/ZUT9Z
MUE4W/6PW\)!DX^M`)!X.*2BH-P[8XI<GVI**`%SD\_K1T&,"DHH`7<:"Q/4D
MTE%`!2YI**`#Z@?E2]1_/WI**`%SQU/YT9)__7244`*"1CMCICM1DXZGFDHH
M`7/K2444`+G-)12T`%5W/SM]:KZMKMEHD>Z^F4-_#$OS.WX?XUS4_B275HR\
M"F"%R1MW98@$CDU:@VKF4Z].#LWJ;E]K,%H2F?,D[A3T^M4U\3#/S0MM]G&?
MY5@YH!Q5\B.66(FWH=E::A!>)F%_F[J>"*L5PZ2-&P:,E6'0@]*V+/Q"R@+>
M@D=G7K^(J7#L;0Q">C-YXTD0I(JLK=01D&N8UCP5%-NETQA"YY\MLE3]/3^5
M=+!/'<1AH'$BGN*EJ5)Q-9TX5%JCR.]LI[";RKN-HW'KW^GK4!&*];O+&#4(
M3%=QI(A[,.GT/45QVL^"I+?=)I3&:,G_`%3??'T]:WA4ON>57P4H*\=4<K13
MI(FB<I*I1UZJPP132,&M#A:L%%%%`@HHHH`***?%$\T@2)2S-T`%#=AI7&XJ
M:ULIKQ]L"%O4]A6Q8>'#Q)?G'I&I_F:W(XTA39$JH@_A48%0YHZZ>$;^(R[#
M0(8,/<_OG[`_='X=ZUJ='$TIP@)J_!IZJ`9AN;L,\"L92OK<]&E225DBI!:O
M<'Y>%'<U?@LTA&2-S>IJP!M&!Q14.3.B,$@QZ_SJ6.X9.#\R^E144BR^D@D^
MZ1GTI:H`D=#CZ5-'<G@.,CUH`LT4`AAE2#]**`"BBB@"Q8_\?<7^]6]6#8_\
M?<7^]6]0!AZG_P`?C_0?RJK5K4_^/Q_H/Y55H`*;*2%&/XJ=3)ONK^-`$5%%
M%`!1110`4444`%%%%`&#JH(O7)_BP1^0JG70WUDMW%\IV2*/E/;\:PY[=[=L
M2*1Z'L?H:TCL<THM,BHHHIDA1110`4444`%%%%`!1110`4444`-F031,OJ.*
MREX'-;"]:QT^Z/I5(Y*\4FA:***I;F`R:9($+RL%11DL2`!7*:SXZCBW1:0J
MROT,K_='T'>H?B"[JUH@=MC%SM[9&T5QW2NFG25KGGXC$SC)QB='IOC>\MY?
M^)A_I,1.3D`,OTQ7::;K-KJL>^SD#$#YE)PR_A7E%:_A[2[BXU"UD0F&/S5_
M>=\9Z"B=-:F>'Q%1.VY[OX.B86MQ(1A9'&W\.O\`.N@-16UO':P)%`H5$&`!
M4E>?)W9]=3AR040HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*4
M]*1B%&7(4`9))KD];\?VUGNBTD+<S=/,S\B_X_YYJE%O8RJUHTHWDSI[N\@L
M(&FO94AC7J6.*XC6_B!+*Q@T)"`>/.<98_1>U<KJ.I7.JW!FOI6D<]!T`]@.
M@K7\'(IFN6*C>H7:WIG.:W4%"-V>;+&3K5%"&B_$;9^&[B_D\_5WD0.<X9LN
MWU]*Z--'@%LB6X,6T8'.?SJ7-68ON`5+DV=5*A3@N]_O,.XM)+8_O%^7LPZ&
MH:Z1U#(P.""*YS&,^QH1G5I\K$H!Q113,R6WNY;5]T#E3W]#]:WK#Q!'*`EW
MB)^@/8USE`XJ7%,N%64-CNE(=05((/0@TM<?9:E-9']TP*=T8<&N@T_5X+T!
M0?+D/\#\?D>]9N+1VPK1EOH-U70K35T/VF/$F.)$&&'^-<3J_A2[TS=)&#<6
MX_C1>0/<5Z1T-)BG&;3,ZV%IU-]SQ['I2$8KT36/"-KJ6Z2#;;3DYW*ORL?<
M#^8KBM3T2ZTB0+=Q_(?NR+]TUO&I%GDUL+4IO78H44459S`.M=%X9A3R9I<#
M>6VY]L9_K7.CK78^&-,F6T)G1HED?<N\8)&!SBHJ-)'7A(-U$70"S849/H*M
MPV!)!F./]FKL5ND(&Q0#W..34E<[EV/8A3MN-1%1<*`!3J**DU"BBB@`HHHH
M`****`)K8D2X[$5:JI;_`.M'T-6Z`"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;
MU`%&[@C,N60$D<G)J'[/%_SS'YG_`!HHI`'V>+_GF/S/^-(;6%NL8X_VC_C1
M10`GV.#_`)YC_OH_XT?8X/\`GF/^^C_C110`?8X/^>8_[Z/^-'V.#_GF/^^C
M_C110`?8X/\`GF/^^C_C1]C@_P">8_[Z/^-%%`!]C@_YYC_OH_XT?8X/^>8_
M[Z/^-%%`!]C@_P">0_[Z/^-,DTZVE4K)"K`]BQ_QHHHNP:ON5_\`A'M._P"?
M4?\`?Q_\:/\`A'M._P"?4?\`?Q_\:**+L7*NP?\`"/:=_P`^H_[^/_C1_P`(
M]IW_`#ZC_OX_^-%%%V+E78/^$>T[_GU'_?Q_\:/^$>T[_GU'_?Q_\:**+L.5
M=@_X1[3O^?4?]_'_`,:='X=TUG`-J,'_`*:/_C11338<J[%G_A%=+_Y]?_(K
M_P"-'_"*Z7_SZ_\`D5_\:**=V'*NP?\`"*Z7_P`^O_D5_P#&C_A%=+_Y]?\`
MR*_^-%%%V'*NP?\`"*Z7_P`^O_D5_P#&H1X)T4=+/_R-)_\`%444KL3IP>Z#
M_A"M&_Y\_P#R,_\`\51_PA6C?\^?_D:3_P"*HHH4GW%[&G_*ON*.H_##PSJQ
M0ZAIOFF/.W_295QGKT8>E4_^%,>#O^@/_P"3D_\`\7115>TFMF2\-1;NX+[D
M/C^#OA")U=-'&5Z9NYB/R+U>C^'/AV)U:/3\,A!4_:)>,?\``J**/:3?4%AJ
M*V@ON1N?V=;_`///_P`>/^-']G6__//_`,>/^-%%2;!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>
M/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`%/4?#&G:M$([^!Y(QSL$[J#]0&&?QK
M._X5MX<_Z!W_`),R_P#Q5%%--K8SE2IRWB@_X5MX<_Z!W_DS+_\`%58L_`^B
M:>6-I9>67QN_?R'./JU%%/FEW!4::=U%?<6O^$9TW_GV_P#(K_XTJ^'-.3.V
MWQG_`*:-_C112NR^5=AW_"/Z>1_Q[_\`D1O\:K?\(;H__/H?^_TG_P`5111=
MB<4]T)_PAFC_`//H?^_S_P#Q5'_"&:/_`,^A_P"_S_\`Q5%%',^Y/)'L'_"&
M:/\`\^A_[_/_`/%4?\(9H_\`SZ'_`+_/_P#%444<S[AR1[!_PANC_P#/H?\`
MO\__`,52CP=I`.1:$$?]-Y/_`(JBBB[*4(]B['HUG$@1(CM7IF1C_,T[^RK7
M_GE_X^W^-%%(H/[*M?\`GE_X^?\`&F2Z+931LDL"NC#!!)(/ZT44`9)^'?AX
MG/\`9_Y7$O\`\51_PKKP]_T#S_X$R_\`Q5%%5S2[F7L*7\J^XEM?`>A6<PE@
ML%$B]"TKMC\V-:7]C6?_`#Q_\?;_`!HHI-M[E1IPCLK!_8UG_P`\?_'V_P`:
M/[&L_P#GC_X^W^-%%(L/[&L_^>/_`(^W^-']C6?_`#Q_\?;_`!HHH`/[&L_^
M>/\`X^W^-']C6?\`SQ_\?;_&BB@`_L:S_P">/_C[?XT?V-9_\\?_`!]O\:**
M`#^QK/\`YX_^/M_C1_8UG_SQ_P#'V_QHHH`5=)M$.5BP?]]O\:?_`&=;_P#/
M/_QX_P"-%%`!_9UO_P`\_P#QX_XT?V=;_P#//_QX_P"-%%`"QV$$3AT3##H=
(QJQ110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g871241002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871241002.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"``S`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]0;K4I8+AT18R%Z9!_P`:A_M>;^[%^1_QJ+4/^/R7ZC^55J`+W]KS
M?W8OR/\`C1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO
M-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_
M=B_(_P"-']KS?W8OR/\`C5&EH`N_VO-_=B_(_P"-']KS?W8OR/\`C7+ZEXGB
ML9VAAB:=T.'.=H!]/>LN7Q9>/D1I!&#T^4DC]:KD9A+$TXZ7.\_M>;^[%^1_
MQH;6944LPA`'<@_XUYO-KE_.H#W,@Q_<PG\L52E=IF+2LSL1]YCD_G5>S,98
MU=$=Y/X]CMQEY[$C.,)EB/P!JE+\4(X_N(LOH4C.#^;"O.71D/S@BFTU!&,L
M9-[([N;XK71!%O96X/8NQ/Z`_P!:K_\`"U-5_P"?;3_^_;__`!5<913Y49O$
M57U.S_X6IJO_`#[Z?_W[?_XJC_A:FJ_\^^G_`/?M_P#XJN,HI\J%[>IW.S_X
M6IJO_/OI_P#W[?\`^*H_X6IJO_/OI_\`W[?_`.*KC**.5![>IW.S_P"%J:K_
M`,^^G_\`?M__`(JC_A:FJ_\`/OI__?M__BJXRBCE0>WJ=SL_^%J:K_S[Z?\`
M]^W_`/BJ='\5=3##S;6Q9>X57!_/<:XJBCE0>WJ=ST"'XK2-_P`?%FB?[F6_
MF15V+XE02XR\,9/9XG'ZYKS*BDX(T6+J+?4]:B\9F=ML$EC(?16R?YU/_P`)
M+<_W+?\`[Y/^->/5-#>7%NN()Y8QZ*Y`J?9FL<;W1ZW_`,)+=?\`/.#_`+Y/
M^-'_``DMU_SS@_[Y/^->9P^)M0A(S,L@`Z/&#_+FKD/C*8$_:;:-_0QL5_QI
M<C-HXNFST#_A);K_`)YP?]\G_&C_`(26Z_YYP?\`?)_QKGM-U.'5(2]ON&T@
M,K#!!JW4/0Z(R4E=&M_PDMU_SS@_[Y/^-'_"2W7_`#S@_P"^3_C6310,UO\`
MA);K_GG!_P!\G_&I[77KB?=O2$;1V!_QK"J[8HR!RPQD<4`:W]KS?W8OR/\`
MC1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_X
MT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_P"-
M']KS?W8OR/\`C5&B@"]_:\W]V+\C_C1_:\W]V+\C_C5&B@"ZVM2H,LL>/8'_
M`!J,^().R1G\#_C5*X_U?XU6H`TSX@N.R0C\#_C1_P`)!<?W(?\`OD_XUF44
M`:?_``D%Q_<A_P"^3_C1_P`)!<?W(?\`OD_XUF4$XH`T_P#A(+C^Y#_WR?\`
M&C_A(+C^Y#_WR?\`&LK=1N-`%'5_B'J-AJ,D$,%DR(%P61B>0#_>JH/B;JS'
M"6UBQ]!$Y_\`9J@U2)'OY&=$+<<E1Z5"`!TK6R['`_:<S]XN3>/O$TO-G!I4
M8QTFM9#_`.U151_'?C=&)$/AAHQZ13[ORWX_6DI#T/T_K3NNQ,HR?VG]Y'!\
M6-?4YN8]'<>B6TBX_$RFIO\`A;6L?\^VF_\`?M__`(NN)_A%%:\D>QP/$UD[
M<S.V_P"%M:Q_S[:;_P!^W_\`BZ/^%M:Q_P`^VF_]^W_^+KB:*.2/87UJM_,=
MM_PMK6/^?;3?^_;_`/Q='_"VM8_Y]M-_[]O_`/%UQ-%')'L'UJM_,=M_PMK6
M/^?;3?\`OV__`,71_P`+:UC_`)]M-_[]O_\`%UQ-%')'L'UJM_,=M_PMK6/^
M?;3?^_;_`/Q=0S_%C7F(^S1:0@QSOMI&_E(*X^BCDCV#ZS6_F.BF^+?C!#^X
MMO#DB^\,RG_T9_6J,_QL\;6XR^CZ,1G'R0R/_*6LNBJ2CV,G5KO:HT32_M#^
M*H'VSZ;HT;?W7MYE/ZR5'_PT?XE_Y\=#_P"_,O\`\<IO48/0]:IS:/8S@B6T
M@Y.253:?S%4E3ZQ,7/&=*K+W_#1_B7_GQT/_`+\R_P#QRN@T3XJ>/=>MH[FR
MTG0!:RYVS2*X!P<'CS<]0>W:N#F\(Z?*1L$T/^X^?YYKT?P78)8>&[6UADWK
M&7))ZC+DX/YTJGLTKQ1O@EBZE6U6H[>3-FS\5^,''^GOX:A.>D-K/+_.1:U[
M?Q;J*Q*+H64DO=HX60'\"Y_G62R%>OYTVN9V9[\(<O5OU.A@\4W<N[=';C`[
M*?\`&K(\17&>8X2/H?\`&N>L_P"/Z5<K-[FJ-<>(I?XHX_P!_P`:D37G<X"I
MGW4_XUB5)!_K5^M(9M?VO-_=B_(_XT?VO-_=B_(_XU1HH`T8=5EDF1&6/#,`
M<`^OUK4KG[7_`(^8?^NB_P`ZZ`=*`,/4/^/R7ZC^55JLZA_Q^2_4?RJM0`44
M44`%%%%`!3)YXK:,R7,L<4:]7=@H'U)I]<%\8<?V/8_]?)_]!-5&/,TC'$U?
M94G4['0WGCC0;''G:I;-G_GB3+_Z`#6+=_%K2(=PM8KRX8?=(0*I_$G(_*O(
M*/Z5U*A%'S\\YKOX4D>C7'QCE8$6FEQH>QDG+?H`/YU8MOC)&7`O-+=%[M%/
MN/Y$#^=>:102S_ZB.23_`'%)JY'H5[*JD0E0W]X@8_#K3=*'8RCF&->S_!?Y
M'07OQ*T2XU.Y,KW-MF1C^]A)_P#0<U;M?$VDWH3[-J%HQ?A5,H5C_P`!/->>
M77@BYGOIGGGAB5G)&T%C^7%3VW@6V3_CXN9I,'^`!!_6K<*=MR(XC%-MN*_(
M]/!!Z'-%3:3IMO;:3911HQ6*!%7+'H%%6_LL7]S]37.VCUHT)-)F:5!Z@4QK
M>-NJ+^`Q6D;*,]"P_&HS8'^%Q^(I70.C-&:UC&>A(J(Z>>S@_A6H;.4=`&^A
M_P`:C,3KG<C#'M3,W%K=&8;*4=@?H:B:&1>J-Q[5J@@G@YHQ0(Q\T5KE%;[R
M@_45&UK$W\(!]J`,RBK[6"'[K$5$U@X/RL#^E`%6BIC:2C^'/T--\B3_`)YO
M_P!\F@".BI!;RGI&WXC%2+92'J`OU-`%>BKBZ?\`WG_(5(+&,=<GZT`9]*%)
MZ`GZ"M18(T'RHOY4\#'2@#6\&6TK6]R0A`\Q>3QV/^-=*MDY^\5'ZUF^#O\`
MCVN_^NB_RKH#UK&:LSU\-_"15%BO\3D_08J06L0_A)^IJ6BI-A%14^XJK]!2
MT44`%%%%`!1110`4444`%%%%`!1110`4444`-E4NF%ZU6:-EZJ?PYJW2T`4<
M45=(!ZC--,2-U44`5*1_O&K1MU[9%0/"0YYH`BHI_E-[4OD\<F@#G]2_X_9/
MP_E5:J'BG4[BUU>>&`JBJ%(;;DGY16%)J5S)]^:3GKAL#\A70H71Y57$QC-H
MZJ21(EW2,J+ZL<"JL^JVL(.Z96..`GS9_*N6)W')Y-%5[,PEBV]D'844459R
M-W84444""BBB@`HHHH`****`"BBB@`HHHH`*56*'*D@CH0:2B@+B:MXBU+3M
M+N)K2\F61%&TN=^.1V;(KG[/XL:Y;*!/]CN^>6EAP?\`QT@?I5_Q'_R!+K_=
M'_H0KSZMZ<(R6J.'%8JO2J+DFT>]_#GQB?&<][&UJ+0VRIR)=^[<3VP,=*[X
M6J+][+?C7CWP"4_;-7;!VA8<G'NU>S&N"O%1J-(^FRRM.KAHSF[O7\Q@AC'1
M!^/-.`QTHHK(]`****`);7_CYA_ZZ+_.N@'2N?M?^/F'_KHO\ZZ`=*`,/4/^
M/R7ZC^55JN7T$KW<A2.1@2,$*?2H/LLW_/&7_O@T`145+]EF_P">4O\`WP:;
M);3\;89>G.$-`##QUI"ZCO2?8[C_`)X3?]\&C['/_P`\)O\`O@T`'FCWJEJ6
MGVFKPB+4K:*XC4Y`D&=I]0>H/TJ[]CG_`.>$W_?!H^QS_P#/";_O@T)V%)*2
ML]CDIOAMH,AREK)%_N3N?YDU%_PKNSB(^RNB;?NEH0S#\<UV7V.?_GA-_P!\
M&C['/_SPF_[X-7[27<Y_JE#^1'$2>$+Q/]6T#@>C$?TJ2'P=<N?W\T,8_P!G
M+'^E=G]CG_YX3?\`?!H%G/\`\\)O^^#1[20+"4TSSNX\*0QW,HGFED(;'R@+
M_C4D>@V,>,0[B.[,3FNLOO#UU+*TD,<AW')4QD52?0=03K:3D>R$U?.V9?5X
M1?PF>`%4!0%4#``&`*6K?]CW_P#SY7?_`'Y;_"C^Q[__`)\KO_ORW^%*Z+L5
M**M_V/?_`//E=_\`?EO\*/['O_\`GRN_^_+?X470[,J45;_L>_\`^?*[_P"_
M+?X4?V/?_P#/E=_]^6_PHNA6*;*'^^`WU&:C:UB/\`!]N*T/['O_`/GRN_\`
MORW^%']CW_\`SY7?_?EO\*+B<$]T9;6*'[K,OUYJ-K%A]UE/UXK8_L>__P"?
M*[_[\M_A1_8]_P#\^5W_`-^6_P`*?,0Z$7T,1K65?X<_0U$59?O*R_48KH/[
M(O\`_GRN_P#ORW^%']D7_P#SY7?_`'Y;_"CF,WAET.>HZ=*W9-!NY`=UA=9P
M<$0,#_*L\:'J6/\`D'WW_@.W^%.Z,9TI1=BE15[^P]2_Z!]]_P"`[?X4?V'J
M7_0/OO\`P';_``IJQ'++L4:*K:Y%KNFR(ECX?U.\WJ262VD(4^^%KGKB3QK,
M"(M`U.#T*:9+D?F#6BIM]3&=51=K/[CJJ*Y&"/QPK_-H^K29Z!],<#]%%;VE
MVWBJXFCCO_#US$'<*9/*D4*">O1J3A;J*%7F^R_N.Y\'?\>UW_UT7^5=`>M5
M-&T"72H'0K+(TK!F/ED`<=*O_99O^>4O_?!KFF[L]ZC%QII,BHJ7[+-_SQE_
M[X-'V6;_`)XR_P#?!J34BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BI?LLW_`#QE
M_P"^#1]EF_YXR_\`?!H`BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BBX#VR;Y8;D
MC_IG;O(?R4$UF7.MO"<0Z5K=QQG,=@X'_CP%-)LB52,=V:=%<S-XEUGYA;^&
MM1]B\4A_0+_6J]K=^*=49Q);3Z<$P05TYCN_[ZS5>S=KLQ^M0YK)-_+_`#.N
MJM/,D))F=4'JQQ6!)H6J3DM=2:U+N'S*"R(?P4"I+?PNT<>V.QNT&23E7//X
MT<J[E*I-_9-"36+.(X:=3_N@M_*HQKUD?^6C#_@!_P`*IOX6N#DQPW0]C$36
M<=#U')_T"]X/_/!O\*?+%D2JU(O5&U=-I6K)MNS;R@="_P`I'T/!_*J,W@K2
M[CYH#+"O_3.7(/YYJG_8FI?\^%[_`-^&_P`*5=&U-&#)8WRD=Q`P_I5;;,RE
M.,OBA<BF^'_RDVUYD]@\7]<_TK-N/!&I0#*+#/[1R8_GBNACAUR(Y2WU$_[T
M+-_,59BFUM,!]/N9/=K9A_*FI21#HT)?9:.$GT/4+<D2V=QP.2L98#\1Q5(J
M0<8->IQWE_N_>Z3?J.^V)C_2I6C^VIMN]-NRHZ++9LP_D::J/JC-X&#^&1Y-
M17J<O@ZRNQN;370GILC>/'X#%9T_PUA=2;?[;$W;*;A^6,_K356)G++ZJVU/
M/:*[&?X9WRX^S2>9SSYD+)C\LUG7'@/7(2=EA)*J_P`2$<_@>?TJE.+ZF$L-
M6CO$Y^BM+_A&=7'_`#"]1_\``5_\*/\`A&M7_P"@7J/_`("O_A3NC/V<^QFT
M5IIX7UB1PJZ7J&2>]LZC\R,5OZ-X(OD$C:CISALC9O7<,?09I.22+IX><Y6L
M<<%)Z#)]*L1Z9=2D!+>7GH2N!^9KT:#PQ-$N%A>,'JJ0$5870)!U@N6^J&H=
M5';'+WU9YY%X<NY!E_+C_P!YO\,U;B\*EB-\_/=53_Z]=ZNCNO2TE_&,FI!8
M7"C"VTP'H(S4.JS>.!IK<XZ#PG`#S%-)Q_&VW_"ISX-MY!C9Y6>XD)/ZYKJ_
ML-S_`,^\_P#W[-'V&Y_Y]Y_^_9J?:2-OJM+L<5=_#FTOH7@N;JY$$@PPCVAN
MN>"01V]*73_A)X5M$Q<6MU=MG.Z>X;_V3:/TKM/L-S_S[S_]^S1]AN?^?>?_
M`+]FFJLUU(^HX:]W!-^>HFG6=EI=LMOID-O:PKR$B0(,^N/7CK5H$-]TY^E5
MOL-S_P`^\_\`W[-'V*Y'2WG_`._9K,ZDDE9%FBF0VUT'&Z*?!ZY0U8^RS?\`
M/&7_`+X-`R*BI?LLW_/&7_O@T?99O^>,O_?!H`+7_CYA_P"NB_SKH!TK#MK>
M5;B(M%(`'&24/K6X*`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
0B@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
